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Due to the considerable increase in public expenditure with health issues, mainly regarding drugs, several 
countries, including Australia and England, have already implemented, or are in the process of discussing 
the adoption of measures to ensure the quality of health care provided to the population. One of the less 
harmful strategies, rarely used in Brazil, is the adoption of economic techniques applied to health, more 
specifically, pharmacoeconomic analysis. This paper aims to contribute to the dissemination of concepts 
and techniques of economic analysis with a view to incorporate these into policy decisions of expenditure 
rationalization and the search for clinical efficiency. It includes a literature review covering the types of 
costs and benefits in health issues, the methodologies of pharmacoeconomic analysis, cost-minimization, 
cost-benefits, cost-effectiveness and cost-utility analysis, as well as its main characteristics, advantages, 
disadvantages and applicability.
Uniterms: Pharmacoeconomy. Pharmacoeconomics analysis.
Em razão do aumento considerável no gasto público com saúde, principalmente no que tange a 
medicamentos, vários países, como Austrália e Inglaterra, já implementaram ou estão em fase de discussão 
da adoção de medidas visando garantir a qualidade do atendimento prestado à população. Uma das 
estratégias menos danosas, mas ainda incipiente no Brasil, é a adoção de técnicas de análises econômicas, 
mais especificamente, a avaliação farmacoeconômica. Neste contexto, este trabalho visa contribuir com 
a disseminação dos conceitos e técnicas de análises econômicas com a perspectiva de que possam ser 
incorporadas nas decisões políticas de racionalização dos gastos e na busca da eficiência clínica. Para 
tanto, este artigo apresenta uma revisão bibliográfica contemplando os tipos de custos e benefícios em 
saúde, as metodologias de análise farmacoeconômicas, quais sejam: análise de minimização de custo, 
de custo-benefício, de custo-efetividade e de custo-utilidade, assim como suas principais características, 
vantagens, desvantagens e aplicabilidades.
Unitermos: Farmacoeconomia. Análise farmacoeconômica.
INTRODUCTION
Pharmacoeconomy is a sub-area of Health Econo-
mics that associates clinical concepts of efficacy, safety 
and quality of various procedures in health care, with 
measures of economic cost. Thus, it can be defined as an 
“application of economic theory to pharmacotherapy” or 
“economic evaluation of drugs” or, it could be placed at 
the interface between two large traditional areas, health 
and economy (Castilho, 1995).
It is a tool that helps to select more efficient options 
(with a good cost/effect relationship) and could help in the 
distribution of health resources in a more just and balanced 
manner. Pharmacoeconomy contributes to the rational use 
of medicines by incorporating cost to questions on safety, 
efficacy and quality of different medical therapies, and 
to the search for a better relationship between costs and 
results. Although employing the word “pharmaco” (drug) 
in its nomenclature, it presents tools that can be equally 
utilized for the assessment of medicines, health programs 
and even of administrative systems, provided that the 
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characteristics inherent to each application are observed 
(Zanini et al., 2001).
In constituting an area of intersection, “conflicts’’ are 
unavoidable due to the diverse forms that health is conside-
red. Traditionally, the professions related to the health area 
are centered on individualistic ethics, according to which 
health has no price and a life saved justifies all effort. On 
the other hand, the economy is underpinned by the ethic 
of common welfare or social ethics. The origin of these 
differences resides in the attitudes of each group regarding 
resource utilization, but both have a vision for the future 
that incorporates resource rationalization and improved 
care rendered in health issues (Del Nero, 2002). Countries 
that have invested in the training and specialization of 
human resources to act at the economy/health interface 
have achieved higher rationalization rates in the process 
of management and quality of health services.
HEALTH PANORAMA
Management of the health/illness processes has re-
quired ever higher amounts of resources especially those 
dedicated to the purchase of medicines. This constant in-
crease can be attributed to several factors including take up 
of new technologies, population aging and the consequent 
rise in chronic-degenerative diseases, efforts to increase 
access to health systems, strategies for the promotion of 
new medicines directed at both the prescribing and the 
consuming classes.
The increased public expenditure with medicines has 
been a cause for concern among governments, because in 
general these rises are higher than inflation or the growth 
in Gross Domestic Product – GDP (Brussels, 2006).
In the USA, health expenses surpassed 1.3 trillion 
dollars in 2000, reaching 2 trillions in 2006, a value equi-
valent to 16% of the GDP. According to projections, this 
percentage is set to increase to 20% by 2015 (Lottenberg, 
2007).
In the United Kingdom, the growth in health ex-
penses is higher than in other sectors of the economy. In 
2001 and 2002, expenses with health represented 17% 
of public expenditure, the greatest proportion since 1948 
(Leatherman et al., 2003).
Medical drugs consume a considerable portion of 
the country’s resources, having a strong impact on ove-
rall health expenses. In Canada, total expenditure with 
medicines increased 11% in 2005, reaching 24.8 billion 
dollars. This expense, the second largest after that of hos-
pitals, has been higher than expenses with medical doctors 
since 2000 (Canadian Medical Association Journal, 2006; 
Buske, 2000, 2004).
In Brazil, according to the National Health Fund 
(Vieira, Mendes, 2007), expenses with health are evolving 
in the same way, although not linearly.
In 2006 the actual expense of the Health Ministry, 
discounting inflation’s impact, reached 23.6 billion reais 
at 2001 prices. In the period between 2002 and 2006, the 
portion of the health budget earmarked for the acquisition 
of medicines increased by 123. 9%, a sum equivalent to 
11% of the total expenditure with health issues in 2006. 
Over the same period, total expenses by the Health Minis-
try increased 9.6 % (Vieira, Mendes, 2007).
In the face of increased expenses and the need of 
at least maintaining the quality of health services, go-
vernments will be obliged to adopt sustaining financial 
measures including tax hikes, cut backs in other areas and 
charging users (Brussels, 2006).
Nevertheless, some countries are adopting less 
damaging strategies, such as the adoption of economic 
analysis during the process of choosing higher priority 
alternatives (Johannesson, Le Lorier, 1996; Briggs, 
Gray, 1999). Such analysis can supply information to 
help managers compare alternatives and decide about the 
best option for their program needs, in a bid to associate 
rationalization of expenses to clinical efficiency. Clinical 
efficiency means maximal attention to quality and user 
satisfaction, with the least possible social costs (Robinson, 
1993a; Russel et al., 1996).
Australia was one of the first countries to incorporate 
economic studies in the devising of therapeutic guides 
and in the adoption of new health practices. In 1993, the 
Australian government, through the Pharmaceutical Be-
nefits Advisory Committee, determined that requests for 
the inclusion of new medicines onto the list of those freely 
distributed to the population, should be accompanied by an 
economic analysis for comparison with current therapeutic 
alternatives (Grobler, 1999).
England created the National Institute for Clinical 
Excellence (NICE), an institution responsible for the 
evaluation of new health technologies always incor-
porating a critical review of existing economic studies 
(Brasil, 2008).
Canada, United States and some European countries 
have recommended economic analyses in the registration 
of new products and in discussions about policies to be 
adopted.
In Brazil, public and private institutions, academic 
or otherwise, base recommendations for the inclusion of 
new drugs in therapeutic guides on medical facts. Howe-
ver, the utilization of pharmacoeconomic information to 
support political decisions remains incipient.
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HEALTH ECONOMY
Del Nero (2002, pg. 19) defines health economy as 
“the branch of knowledge that has as its objective the op-
timization of health actions, meaning the study of optimal 
conditions for the distribution of available resources to 
assure the best health assistance and conditions to the po-
pulation, taking into account the limited means available”.
The World Health Organization divides health eco-
nomy into Health Macroeconomics and Health Microe-
conomics. The first aims to develop economic studies on 
health in general and its relations with other socioecono-
mic sectors whilst the second is dedicated to the study of 
different health components (WHO, 1976).
Health economics exploit relevant topics in its field 
of application: the role of health services in the economic 
system; the system of production and distribution of health 
services; the ways of measuring the impact of investments 
in health; the study of health indicators and levels corre-
lated to economic variables; the employment and salary 
of healthcare professionals and the work force available; 
the health industry in advanced capitalism; the behavior 
of service providers and their relations with the consumer; 
the cost-benefit analysis, cost-effectiveness analysis, and 
cost-utility analysis of services or specific goods (Del 
Nero, 2002), such analysis being the major components 
of pharmacoeconomy.
In the commonly used definition established by 
Townsend (1987), pharmacoeconomy represents the “des-
cription and analysis of medical therapy cost to health sys-
tems and society”. In this broad concept, the term includes 
all aspects of the medical economy: its impact on society, 
on the chemo-pharmaceutical industry, on pharmacies, on 
national formularies, stating that nearly all areas related 
to medical drugs are connected with economic issues 
(Sacristan Del Castillo, 1995).
The International Society for Pharmacoeconomics 
and Outcomes Research – ISPOR defines pharmacoe-
conomy as the “field of study that evaluates individual, 
enterprise and market behavior in relation to the use of 
products, services and pharmaceutical programming, and 
frequently focuses on costs, and the consequences of its 
utilization” (Pashos, Klein, Wanke, 1998).
Pharmacoeconomy comprises the valuation of tech-
nical yields, of clinical efficiency, security, economic effi-
cacy, organizational impact and of its social consequences 
and ethical implications (Mossialos, 1997).
Pharmacoeconomic evaluation identifies, quantifies 
and compares costs (resources used for pharmaceutical 
products and services) and consequences (economic, 
clinical and humanistic) of its utilization, thus allowing 
identification of the results of actions in the health area 
as an economic indicator of its efficiency or efficacy, in 
addition to helping optimize resource use and decision 
making. Its costs represent financial investment in health. 
Traditionally, health costs have been classified as direct, 
indirect and intangible, fixed and variable (Drummond et 
al., 1997). Direct costs are those directly associated with 
medical care and medical drugs (Robertson, Lang, Hill, 
2003), and may be classified into: a) sanitary or medical, 
related to drugs or medical care (purchase, cost of medi-
cine supply and administration, hospitalization, consulta-
tions, diagnostic evidence); and b) non-sanitary or non-
medical, encompassing those related to the furnishing of 
medical services including patient transportation, family 
care, and special nutrition (Carlos et al., 2001).
Indirect costs are related to loss of the productive 
capacity of individuals faced with the process of getting 
sick or of an early death. They represent loss of working 
days, inability to perform professional activities, loss of 
time on trips to receive health care, and premature death 
secondary to disease (Bombardier, Eisenberg, 1985; Villar, 
1995; Lew, Forgia, Sulvetta, 1996). Due to the difficulty 
of objectively estimating indirect costs, some institutions, 
including the Australian Pharmaceutical Benefits Advisory 
Committee, have set up directives that exclude indirect 
costs (Department of Health and Aged Care, 1994). Ne-
vertheless, the National Institute for Clinical Excellence, 
2001, recommends that these costs be calculated separa-
tely so that the impact of their exclusion can be evaluated 
(Nice, 2001).
Intangible costs are those associated with pain and 
suffering, and are the most difficult to quantify and eva-
luate, although up to a certain point they are incorporated 
in the services ascribed to illnesses that reflect quality of 
life (Robertson, Lang, Hill, 2003).
Costs may be variable or fixed. Fixed costs are tho-
se that do not vary with the amount of goods or services 
rendered, while variable costs are those that vary with the 
amounts produced (Mankiw, 2001).
The concept of opportunity or social costs reflects 
the scarcity or limitation of resources. It is related to 
benefits derived from the utilization of resources by the 
alternative of best use. Therefore, it is a measure of the 
sacrifice made by society for the use of resources in a 
given program, as they will no longer be available for use 
in others (Griffiths, 1981; Mills, Drummond, 1985).
The consequences or benefits, in turn, may be eco-
nomic (economy or economic benefits), clinical, i.e. a 
consequence of a pharmacological treatment or strategy 
(deaths, morbidities and other specific clinical indicators) 
or humanistic, resulting from the disease or treatment in 
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the patient’s functional condition or their quality of life 
measured according to diverse dimensions (satisfaction, 
general health, physical functions, social functions, life 
expectancy or quality, etc.) (Venturini, Johnson, 2002; 
Zanini et al., 2001).
The economic benefits associated with improved 
patient health conditions can be measured in the following 
ways (Reinhardt, 1997): direct benefits, representing 
resources not spent in relation to costs resulting from me-
dical assistance, for example cases of mammary cancer 
avoided by investing in a prevention program; and indirect 
benefits, which are gains in productivity and to society. He-
alth recovery and deaths prevented increase the number of 
people able to work and produce for the benefit of society.
For a full understanding of the techniques of econo-
mic evaluation, it is important to also describe the concepts 
of efficacy, effectiveness and efficiency.
Efficacy refers to the benefits, consequences and 
results (outcomes) of drugs utilized under ideal condi-
tions, that is, during application in clinical trials mainly 
using rigorous criteria of patient selection, the follow up 
of their clinical evolution and strict compliance with their 
therapeutic regime. Effectiveness measures the results of 
the utilization of medicines in daily clinical practice, thus 
evaluating it under habitual real conditions. It should be 
noted that effectiveness is frequently lower than efficacy. 
Efficiency represents the relation between the financial 
resources (costs) and outcomes, utilized in a given inter-
vention (Jolicoeur, Jones-Grizzle, Boyer, 1992; Sacristan 
Del Castillo, 1995; Bootman, Townsed, Mcghan, 1996).
From a health perspective, a program or treatment is 
considered efficient when it attains the maximum degree of 
health possible by the given resources or, when the result 
obtained by the choice, is at least equal to the opportunity 
cost. It is also efficient when, comparing options that 
produce the same result, it is elected the least expensive 
(Sacristán et al., 2004).
According to Carlos et al. (2001) and Gold et al. 
(1996), the economic evaluation is carried out prior to the 
decision on its implementation, so that costs and effects 
of its application will occur in future. In these cases, when 
the costs and effects are produced in a period longer than 
one year, it will be necessary to transform them into units 
equivalent to those of the year zero (the time when the 
evaluation is performed). This correction is justified in 
part because society values results about health more when 
reached in the present than those that might be obtained in 
the future, and because in general, one prefers to postpone 
costs, rather than carry them in the present. An extensive 
debate prevails in the literature about an appropriate dis-
count tax that should reflect the individual’s preference to 
negotiate future gains (or losses) against present ones. The 
Cost-Effectiveness Panel recommends a discount tax of 
3% (Russel et al., 1996).
In pharmacological evaluation, several methods 
can be utilized, from simple cost minimization analysis 
to more comprehensive cost-benefit, cost-effectiveness 
and cost-utility analysis. The methods vary according 
to the objective and the analysis perspective. Therefore, 
pharmacoeconomic analysis do not decide on medicinal 
policy, but play an important factor in decision taking.
Data for pharmacoeconomic analysis are obtained 
from controlled clinical assays (randomized studies), ob-
servational studies, economic models (primary sources), 
and retrospective studies, the opinion of a clinical specia-
list, evaluations of the medicine uses, and the literature 
(secondary sources) (Zanini et al., 2001). The use of these 
sources depends on published data, the quality of retros-
pective data bases, human and monetary resources, and the 
relative importance of the decision (Zanini et al., 2001).
TYPES OF PHARMACOECONOMIC EVALU-
ATION
Cost Minimization Analysis
Cost Minimization Analysis (CMA), one of the 
simplest economic evaluations, is utilized when the result 
of two or more interventions are the same in terms of their 
clinical consequences. In CMA, only costs are submitted 
for comparison, because the efficacy or effectiveness of 
comparable alternatives are equal. (Eisenberg, 1989; Joli-
coeur, Jones-Grizzle, Boyer, 1992; Sacristan Del Castillo, 
1995; Bootman, Townsend, Mcghan, 1996; Drummond 
et al., 1997). This approach is justified when alternatives 
of comparable programs or therapies produce clinically 
equivalent results, as in decision taking of pharmothera-
peutic guides (Carreira-Hueso, 1998; Drummond, 1991). 
Thus, the first critical step prior to conducting a CMA is to 
determine the therapeutic equivalence of the interventions 
(Robertson, Lang, Hill, 2003). When intervention results 
differ, it is not possible to proceed to cost minimization 
analysis. An example of CMA is the analysis of adminis-
tration costs of the same medicine given using different 
routes of administration (Przybylski et al., 1997).
Cost Benefit Analysis (CBA)
Cost Benefit Analysis (CBA) establishes the rela-
tionship between costs associated to treatment and finan-
cial benefits generated by it. All cost (investments) and 
benefits (consequences) of alternatives are measured in 
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monetary terms so that it will be possible to verify whether 
the benefits exceed the expenses for each intervention. 
Among other aspects, the return of applied resources in 
a health issue may be compared with gains obtained by 
investments made in other areas of the economy (Robin-
son, 1993a). Examples: (i) the relationship of treatment 
costs and the economy of resources resulting from shorter 
patient hospital stay; (ii) the costs of a vaccination program 
and the resources yielded by the reduction of absences 
from work or the number of hospital admissions; (iii) the 
costs of a program of early treatment of diseases versus 
delayed treatment or its complications etc. (Zanini et al., 
2001).
The results of cost-benefit analysis are present in the 
form of liquid benefits, that is, benefits of the intervention 
minus the costs of intervention (Brasil, 2008). This type 
of instrument evaluates the economic viability of social 
projects, it can be applied to a given program or to various 
alternative ones in order to compare them in terms of their 
“social profitability’. This presumes the concept of progra-
ms in the social area (health, education etc.) as investments 
in human capital, in the sense that these programs, whether 
for empowering or rendering the work force healthier or 
increasing their productivity, boost the productivity of the 
economic system as a whole. The theoretical basis of this 
technical instrument therefore becomes evident: the theory 
of human capital and the methodology of the economic 
analysis of investments (Ugá, 2002).
Thus, these studies show the theoretical advantages 
of facilitating choices between health and non-health pro-
grams (for example, between subsidizing a new drug and 
increasing funds for school transportation) (Brinsmead, 
Hill, 2003), and of providing subsidies to public adminis-
trators and to society for taking better informed decisions 
and enabling the optimization of resource utilization.
This type of analysis has the inherent inconvenience 
of the difficulty attributing monetary value to the results 
and to life, not permitting simultaneous comparisons of 
products with more than one indication. Intangible be-
nefits, such as the subjective health expression of each 
patient and the value of human life, are obviously very 
difficult to be expressed in monetary terms. Furthermore, 
the evaluation of benefits to persons that do not have an 
economic activity becomes impaired. This type of analysis 
has often been criticized for ignoring important benefits 
resulting from health programs and for concentrating on 
items of easy measurement. Initially, it was the most used 
analysis, but due to the difficulty of attributing monetary 
values to human life, cost-effectiveness is currently more 
utilized (Carreira-Hueso, 1998; Drummond, 1991; Ro-
binson, 1993b).
Cost Effectiveness Analysis (CEA)
Cost Effectiveness Analysis (CEA) concerns the 
relationship between the cost of a treatment, measured in 
monetary units, and its clinical benefits (effectiveness) to 
the patient. Results are expressed in non monetary units, 
that is, in terms of improved health or natural units (leng-
thened life span, number of lives saved, clinical cures, 
days free of symptoms or pain, cost/hour of nursing time, 
cost/mercury millimeter of altered arterial blood pressure) 
(Drummond, Jefferson, 1996; Walley, Haycox, 1997; Za-
nini et al., 2001). Thus, the unit of measurement selected 
will depend on the objective of the program or treatment 
evaluated (Pinto-Prades, Ortún-Rubio, Puig-Junoy, 2001).
In general terms, CEA is the most appropriate te-
chnique when the choice has to be made between two or 
more competing options, for which the gains expected 
in health can be expressed in terms of a measuring com-
mon effect (Lopert, Lang, Hill, 2003). Therefore, CEA is 
always comparative and considered in the choice of the 
best strategy to attain the same objective (Detsky, Naglie, 
1990; Drummond, 1994; Ugá, 2002). Examples include 
the relationship between costs of treatment by different 
antihypertensive agents and the respective degrees of 
effectiveness in decreasing the patient’s arterial pressure, 
or costs of different chemotherapy treatments against can-
cer and their respective degrees of effectiveness in saving 
or extending lives (Zanini et al., 2001).
CEA represents the type of analysis most utilized 
in pharmacoeconomy, because it enables the use, in daily 
practice, of the same units utilized in clinical assays. 
The calculation of the cost-effectiveness ratio 
expresses the additional cost required to reach an extra 
unit of clinical benefit and is expressed by the difference 
between the cost of two interventions, divided by the 
difference between their consequences in terms of health 
(effectiveness) (Brasil, 2008).
Another measurement unit of cost-effectiveness is 
the quality of life related to health (QLRH). The two major 
types of QLRH are: a) those which are specifically named, 
formulated to evaluate improvements in the quality of life 
produced by a specific treatment; and b) those generically 
named, developed to evaluate variations in life quality 
produced by any type of intervention (Pinto-Prades, Ortún-
Rubio, Puig-Junoy, 2001).
The analysis of cost-effectiveness however, has limi-
tations. As already noted, it may be useful for determining 
expense priorities in different treatments for the same 
condition (technical efficiency), but is less applicable in 
decisions concerning treatment for different diseases. It is 
not possible to compare programs (or even within the same 
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program) when a common measure does not exist. One 
cannot compare cost-effectiveness of an antihypertensive 
therapy and one for asthma, where effects of treatment are 
described in terms of reduction of blood pressure in the 
first case, and the percentage of increased forced expiration 
volume, in the second (Lopert, Lang, Hill, 2003).
However, in several studies that work with effects 
(such as the number of deaths prevented) and not with 
products (vaccination, number of houses attended with 
sewers, etc.) this restriction may be effectively overcome 
in the sense that strategies of intervention are compared 
with totally distinct products (expansion of the health 
system, immunization, maternal-infant care, for example) 
(Ugá, 2002).
Cost Utility Analysis (CUA)
Cost Utility Analysis (CUA) considers the rela-
tionship between costs of a treatment and its benefits to 
the health-related quality of life of the patient (utility), as 
well as the risks of adverse drug reactions. This method 
combines patient satisfaction and preference with cost-
effectiveness analysis. It is applicable in studies aimed at 
comparing different treatments mainly targeted to chronic 
patients. Examples include relationship between the cost 
of different cancer treatments and their respective life 
quality indexes, related to patient health during the extra 
years that they have gained; cost for a rheumatoid arthritis 
treatment and the health-related quality of life the patient 
started to lead following pain reduction and improved 
mobility. However, it does not allow comparisons between 
different sectors, for example, health costs in relation to 
education (Walker, 2001).
In Cost Utility Analysis, cost to obtain “one year of 
healthy life” is calculated with different treatments that 
is, it incorporates the amount and also the quality of life 
in the years that were saved by means of a treatment. The 
results (output) are expressed as the cost for the “years of 
healthy life” or “years of life adjusted for quality “(QALY 
– quality-adjusted life-years). QALYs are calculated by the 
years of life gained, multiplied by a quality index, verified 
by means of specific questionnaires. Modern medicine is 
concerned about the improvement of life quality and not 
only about longevity of life (Drummond, 1991; Robinson, 
1993b).
The use of life expectancy adjusted for quality ena-
bles the evaluation of situations in which there is increased 
survival under health conditions that are not perfect or 
therapies that do not alter survival, but improve quality of 
life (Brasil, 2008).
CUA is presently the economic evaluation approa-
ch preferred by specialists, mainly because it allows the 
comparison of different programs or treatments without 
the ethical problems occurring in CBA over attributing 
monetary values to health. The use of lists of treatments 
and health programs classified according to their cost 
per QALY, has helped the setting of priorities in health 
issues. The lower cost treatments per QALY should be 
implemented first, and those with higher cost per QALY 
should be considered of lesser priority. However, although 
useful, this cannot be the sole criterion employed in the 
setting up of health priorities (Pinto-Prades, Ortún-Rubio, 
Puig-Junoy, 2001).
Thus, pharmacoeconomic analysis considers the 
economic factors in the utilization of medicines, but does 
not exclude clinical and humanistic results as important 
subjects for evaluation. The real value of an intervention 
or policy can only be found when all dimensions of the 
result are measured and taken into consideration. Viewed 
in this manner, the economic criterion cannot perform the 
major role.
Table I illustrates, in summarized form, the major 
characteristics of each type of analysis.
SENSITIVITY ANALYSIS
Sensitivity analysis takes into account the uncer-
tainties common to economic evaluations of health, since 
the results found in clinical practice can vary in relation 
to results reported in the medical literature. Thus, this 
type of analysis recalculates the cost-effectiveness ratios 
obtained, modifying one or more parameters of the study. 
Examples of variables are the degree of effectiveness of 
the intervention, the natural course of the disease, the costs 
related to the treatment, the expected result in life quality, 
among others.
The Panel of Cost-Effectiveness in health recom-
mends the use of this technique in economic health eva-
luations and suggests the calculation of all parameters or 
variables of the model whose estimation are not precise or 
whose values may vary in different settings (Brasil, 2008).
Sensitivity analysis can be conducted modifying 
one or numerous variables of the model simultaneously.
If, on varying the values of a given parameter the 
chosen strategy remains stable, one states that the model is 
insensitive to this parameter and the lack of precision in its 
estimate does not decrease the validity of the conclusions 
obtained by the model (Reinhardt, 1997).
In developed countries, cost analysis are frequently 
employed for managers to gain adequate information 
when defining and choosing priority interventions in the 
health area.
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In Brazil, as in other developing countries, this 
practice has not been adopted (Médici, 1994). The con-
ducting of economic studies is still rare in the country and 
concentrated in academic institutions.
Arredondo and Damian, 1997, emphasized the need 
for identifying and controlling the costs of services as a 
priority problem for the system’s organization. Therefore, 
it is important that the government and health systems 
become involved with the spreading of concepts and 
techniques of economic analysis, investing in the educa-
tion and training of qualified human resources and stimula-
ting the production of studies applying these tools, both in 
public and private sectors, and actually start to incorporate 
economic analysis into policy decisions on health issues.
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TABLE I - Types of pharmacoeconomic analysis
Type of 
Analysis
Characteristics Advantages (V) 
Disadvantages (D)
Measure of 
Costs
Measure of 
Effects
CMA Finds the program of least cost 
among those of equal benefit
Includes only limited costs (inputs) (D) 
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